New preprint 🔥 showing that blocking JAK1/2 with ruxolitinib boosts food intake, preserves fat, and extends survival in lung cancer–associated cachexia. @eze_dantas https://t.co/n9FER7D3C9
#CancerMetabolism#Cachexia#LungCancer#JAKSTAT
An antibody therapy from @NussenzweigL was found to control HIV for months in a new clinical trial. Treatment with broadly neutralizing antibodies does not rely on vigilant daily dosing and could potentially reduce the body’s reservoir of latent viruses.
https://t.co/PbUoNegZYR
Our paper "Evolution of antibody immunity to
SARS-CoV-2" has been selected as the 2021 Paper of the Year by the International Society for Vaccines! What a nice surprise and acknowledgment of the fantastic work by everyone involved and all 42 (!) authors!🙏
https://t.co/weYBStHWMV
Also out today: Our new preprint with @theodora_nyc and @NussenzweigL: Differences in antibody evolution following infection vs vaccination.
https://t.co/B3ziTcShdH
Our paper showing long lasting and continuously evolving antibody immunity one year after SARS-CoV-2 infection is out today in @Nature. Brought to you by the commitment of our fantastic study participants 👏@RockefellerUniv@NussenzweigL
June 5th marks the 40th anniversary of the first reported cases of what later became known as HIV.
It is an opportunity to remember what we’ve learned so that it can help inform our future.
We CAN #StopHIVTogether. #40YearsOfHIV
“People who were infected and get vaccinated really have a terrific response, a terrific set of antibodies, because they continue to evolve their antibodies,” Dr. Nussenzweig said. “I expect that they will last for a long time.”
Una gran orgullo de nuestro equipo! Hoy lanzamos, finalmente, la plataforma COVID-T que permitirá estudiar la memoria de linfocitos T anti-SARS-CoV-2 en pacientes recuperados de COVID-19 e individuos vacunados. @MontanaManselle@veigas, @nicoitorres@AdaGBB @tomasdalotto
We set a goal to FULLY re-open New York City on July 1!
This is going to be the #SummerOfNYC and there's never been a better time to be a New Yorker. Our city is ready to come back strong.
We're starting recruitment for a new post-doc interested in diet, cancer, and metabolism. Cell, mouse, and human studies ongoing. Share with any obesity/metabolism students looking to broaden into cancer or cancer biologists interested in diet/metabolism. https://t.co/eS1znFmLWa
Read about how the Immune system evolves To fight Coronavirus variants - which includes some thoughts from Michel #antibodies#covid https://t.co/w9Eyc8gC3P via @sciam
The neutralizing activity of the Moderna and Pfizer-BioNTech vaccines against SARS-CoV-2 is reduced by a small margin against the variants N501Y, E484K and the combination K417N:E484K:N501Y, according to a Nature paper. https://t.co/UXAOQbNK7N
We are still seeking volunteers for our study of two investigational antibodies directed against SARS-CoV-2, the virus that causes COVID-19. These antibodies are being developed to potentially prevent and treat COVID-19. 👇
Today we’re announcing a license agreement with @RockefellerUniv to develop and commercialize antibodies against SARS-CoV-2 for the potential treatment of #COVID19. https://t.co/ZmfBAxGdFX
We are excited to see our anti-SARS-CoV-2 antibodies move forward in clinical development! The agreement with BMS is crucial to bring this potential treatment of COVID-19 into patient care quickly and enable global availability using a low dose subcutaneous administration.
Breton, Mendoza, Hägglöf, @NussenzweigL et al show that #SARSCoV2 infection elicits broadly reactive & highly functional T cell responses, & recovered patients show persistent alterations in CD4+ & CD8+ T cell memory compartments https://t.co/4V4QFUHOH7 @RockefellerUniv#COVID19